Abstract: A formulation is disclosed comprising a pharmaceutically acceptable admixture of an osteogenic protein and a sponge of porous particulate polymer matrix. The sponge may be prepared by treating the porous particulate polymer matrix with a suitable fusing material such as ethanol and a surfactant such as a polysorbate.

Abstract: A process for increasing the yield of recombinant bone-inducing proteins of the BMP-2 family is provided, wherein dextran sulfate is added to the culture medium in which cells expressing the proteins are grown.

Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.

Abstract: DNA molecules encoding mutant forms of bone morphogenetic proteins (BMP) are disclosed, The mutant forms of BMP can be produced bacterially and refolded to produce biologically active homodimers or heterodimers of BMP. A method of making such mutant BMPs is also disclosed.

Abstract: A method for detecting the presence of small mounts of contaminant DNA, present in an amount of at least about 0.1 picogram of DNA, in a protein product produced by recombinant DNA technology. The method comprises using oligonucleotides with sequences directed to those of repetitive host cell line DNA sequences, as primers in a PCR reaction. Also disclosed are kits for the detection of small amounts of contaminant DNA in a protein product.

Abstract: A composition is disclosed comprising a pharmaceutically acceptable admixture of an osteogenic protein; a porous particulate polymer matrix; an osteogenic protein-sequestering amount of blood clot; and a calcium sulfate hemihydrate-containing substance. Also disclosed are formulations of bone morphogenetic proteins with improved solubility and/or stability characteristics.

Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.

Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for reducing or removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.

Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.

Abstract: The present invention provides a novel method to purify green-plant phytochrome; the production of hybridoma cell lines secreting monoclonal antibodies specific for green-plant phytochrome and that do not cross-react significantly with etiolated-plant phytochrome; a partial amino acid sequence for an immunoaffinity-purified green-plant phytochrome; oligonucleotide probes for cloning green-phytochrome genes from plant genomic DNA and cDNA libraries; and cloned green-phytochrome genes and cDNA.

Abstract: A novel process for the direct transfer of foreign genes to plant genomes is described. The novel process comprises placing a gene under the control of plant expression signals and transferring it, by contact with protoplasts without the aid of natural systems for infecting plants, directly to plant cells from which genetically transformed plants can subsequently be derived.

Abstract: A process for the maintenance and proliferation of defective, non-infectious viruses or virus genomes, comprising mutations, i.e. deletions, substitutions, insertions and new rearrangements of the viral genes or combinations of the virus DNA with heterologous genetic material in proliferating plant material and for the regeneration of whole plants containing stably integrated into their genome said defective, non-infectious virus DNA.

Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.

Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.

Abstract: The invention concerns a peptidylhydroxyglycine N-C lyase (PHL) catalyzing the reactionR-GlyOH.fwdarw.R-NH.sub.2wherein R represents a peptide residue, and GlyOH represents an .alpha.-hydroxyglycine residue linked to the C-terminus of said peptide R by an amide bond, a recombinant DNA molecule coding for a PHL, a method for the preparation of such a recombinant DNA molecule, processes for the preparation of PHL from a natural source or by means of the said recombinant DNA molecule, and the use of PHL for the preparation of an amidated peptide R-NH.sub.2.

Abstract: There is provided a pharmaceutical composition comprising as component A a plasminogen activator and as component B hirudin together with a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the prophylaxis and therapy of thrombosis or diseases caused by thrombosis.

Abstract: Insulin-like growth factor I (IGF I) and pharmaceutical compositions comprising IGF I are useful in improving glomerular filtration and renal plasma flow and can be used for the treatment of patients suffering from renal diseases and for the preparation of therapeutic combinations for treatment of renal diseases.

Abstract: The invention relates to plant cells and dicotyledonous plants transformed with chimeric rat glutathione-S-transferase gene constructs. Transgenic tobacco plants and progeny expressed the chimeric gene constructs under the control of a plant promoter. The transgenic plants and progeny demonstrated resistance to a herbicide which is normally inhibitory to plants not expressing the chimeric construct.

Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.

Abstract: Methods and nutrient media are disclosed useful for adapting mammalian cell lines to culture at increased cell densities.